Andrew H. Ko

17.1k citations

150 papers · 4.9k indexed · 1 hit paper · h-index 35

Impact in

Oncology top 0.5%
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
Cancer Research top 0.5%
- Cancer Genomics and Diagnostics

Papers in

Oncology 124
- Pancreatic and Hepatic Oncology Research 93
- Colorectal Cancer Treatments and Studies 24
- Cancer Immunotherapy and Biomarkers 20
- HER2/EGFR in Cancer Research 9
Cancer Research 49
- Cancer Genomics and Diagnostics 46

Co-authors: Margaret A. Tempero Alan P. Venook Eric A. Collisson Emily K. Bergsland Grace Kim Adam B. Olshen Peter Olson J. Cooc
Journals: Journal of Clinical Oncology (61 papers)Pancreas (7 papers)Annals of Oncology (6 papers)The Oncologist (6 papers)Clinical Cancer Research (4 papers)
Partner nations: United States Spain United Kingdom

In The Last Decade

Andrew H. Ko

146 papers receiving 4.8k citations

Hit Papers

align trajectories log scale

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy 2011 · 1.2k citations

Peers

Countries citing papers authored by Andrew H. Ko

Since Specialization

Citations

This map shows the geographic impact of Andrew H. Ko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew H. Ko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew H. Ko more than expected).

Fields of papers citing papers by Andrew H. Ko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew H. Ko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew H. Ko. The network helps show where Andrew H. Ko may publish in the future.

Co-authors

The 25 scholars most cited alongside Andrew H. Ko, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew H. Ko Line = papers co-authored together Andrew H. Ko links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study PubMed ·Samuel J. Klempner, Roberto Pazo-Cid, Sara Lonardi, Laura C Swanson, Matthew J. Arango, Peter C. Enzinger, Andrew H. Ko, Gina M. Vaccaro, K. Yamaguchi, Anwaar Saeed, K.-W. Lee, Kohei Shitara, David H. Ilson, Jaffer A. Ajani, Rupali Fuldeore, Stéphanie Braun, Michael S. Broder, Manali Shah	2025	4
2	Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2 JCO Precision Oncology ·Erica S. Tsang, Mallika Sachdev Dhawan, Romain Pacaud, Scott Thomas, Jennifer A. Grabowsky, Lauren Wilch, Silpa Karipineni, Robin Kate Kelley, Andrew H. Ko, Eric A. Collisson, Jocelyn Chapman, Stefanie Ueda, Emily K. Bergsland, Pamela N. Münster	2024	1
3	Maintenance Treatment for Metastatic Pancreatic Cancer: Balancing Therapeutic Intensity with Tolerable Toxicity Cancers ·Evan J. Walker, Andrew H. Ko	2023	1
4	The jaw‐dropping costs of oral cavity cancer malpractice Head & Neck ·Amanda Wong, Daniel Zhu, Jane Y. Tong, Andrew H. Ko, Tristan Tham, Dennis H. Kraus	2021	3
5	Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma The Oncologist ·Evan J. Walker, Dena Goldberg, Kelly Gordon, Christina Pedley, Julia Carnevale, Pelin Cinar, Eric A. Collisson, Margaret A. Tempero, Andrew H. Ko, Amie Blanco, Mallika Dhawan	2021	23
6	A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer Clinical Cancer Research ·Annie A. Wu, Katherine M. Bever, Won Jin Ho, Elana J. Fertig, Nan Niu, Lei Zheng, Rose Parkinson, Jennifer N. Durham, Beth Onners, Anna Ferguson, Cara Wilt, Andrew H. Ko, Andrea Wang‐Gillam, Daniel A. Laheru, Robert A. Anders, Elizabeth D. Thompson, Elizabeth A. Sugar, Elizabeth M. Jaffee, Dung T. Le	2020	91
7	Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation Journal of Gastrointestinal Cancer ·Marissa B. Savoie, Alan Paciorek, Li Zhang, Erin L. Van Blarigan, Nilli Sommovilla, Donald I. Abrams, Chloé E. Atreya, Emily K. Bergsland, Hueylan Chern, Robin Kate Kelley, Andrew H. Ko, Angela Laffan, Ankit Sarin, Madhulika G. Varma, Alan P. Venook, Katherine Van Loon	2018	20
8	CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer Annals of Oncology ·Andrew H. Ko, Antonio Cubillo, Madappa N. Kundranda, Syed F. Zafar, Eyal Meiri, J. C. Bendell, Hana Alguel, F. Rivera Herrero, E. Ahn, D. Watkins, Uwe Pelzer, V. Charu, W. Downing, B. Wang, Geoffrey Kuesters, J. Marc Pipas, Sergio Santillana, Vasileios Askoxylakis	2018	8
9	Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Journal of Clinical Oncology ·Dung T. Le, Andrew H. Ko, Zev A. Wainberg, Vincent J. Picozzi, Hedy L. Kindler, Andrea Wang‐Gillam, Paul E. Oberstein, Michael A. Morse, Herbert J. Zeh, Colin D. Weekes, Tony R. Reid, Aimee Murphy, Katherine McDougall, Chan C. Whiting, Nitya Nair, Amanda Enstrom, Sandy Ferber, Thomas W. Dubensky, Dirk G. Brockstedt, Elizabeth M. Jaffee	2017	39
10	A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma Clinical Cancer Research ·Andrew H. Ko, Tanios Bekaii‐Saab, Jessica Van Ziffle, Olga K. Mirzoeva, Nancy M. Joseph, AmirAli Talasaz, Peter Kühn, Margaret A. Tempero, Eric A. Collisson, Robin Kate Kelley, Alan P. Venook, Elizabeth Dito, Anna Ong, Sharvina Ziyeh, Ryan Courtin, Regina Linetskaya, Sanaa Tahiri, W. Michael Korn	2015	100
11	Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Cancer Discovery ·Oliver A. Zill, Claire Greene, Dragan Sebisanovic, Lai Mun Siew, Jim Leng, Mary Vu, Andrew Hendifar, Zhen Wang, Chloé E. Atreya, Robin Kate Kelley, Katherine Van Loon, Andrew H. Ko, Margaret A. Tempero, Trever G. Bivona, Pamela N. Münster, AmirAli Talasaz, Eric A. Collisson	2015	202
12	Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma Hematology/Oncology Clinics of North America ·Erqi L. Pollom, Albert C. Koong, Andrew H. Ko	2015	8
13	Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma Molecular Cancer Therapeutics ·Olga K. Mirzoeva, Eric A. Collisson, Peter M. Schaefer, Byron Hann, Yun K. Hom, Andrew H. Ko, W. Michael Korn	2013	34
14	Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates Annals of Oncology ·Robin Kate Kelley, Halla Nimeiri, P.N. Munster, Maxwell T. Vergo, Yazhong Huang, Caixia Li, Justin H. Hwang, Mary F. Mulcahy, Benjamin M. Yeh, Peter Kühn, Madelyn Luttgen, Jennifer A. Grabowsky, Lisa Stucky-Marshall, W. Michael Korn, Andrew H. Ko, Emily K. Bergsland, Al B. Benson, Alan P. Venook	2013	50
15	A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer British Journal of Cancer ·Andrew H. Ko, Margaret A. Tempero, Y-S Shan, Wu‐Chou Su, Yulin Lin, Elizabeth Dito, A. Ong, Y-W Wang, Chen‐Hao Yeh, L-T. Chen	2013	126
16	A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer Cancer Chemotherapy and Pharmacology ·Andrew H. Ko, Thach‐Giao Truong, Emily Kantoff, Kimberly Jones, Elizabeth Dito, Anna Ong, Margaret A. Tempero	2012	21
17	Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology Journal of Clinical Oncology ·Nicholas J. Vogelzang, Steven I. Benowitz, Sylvia Adams, Carol Aghajanian, Susan M. Chang, ZoAnn E. Dreyer, Pasi A. Jänne, Andrew H. Ko, Greg A. Masters, Olatoyosi Odenike, Jyoti D. Patel, Bruce J. Roth, Wolfram E. Samlowski, Andrew D. Seidman, William D. Tap, Jennifer S. Temel, Jamie H. Von Roenn, Mark G. Kris	2011	68
18	A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer Cancer Chemotherapy and Pharmacology ·Andrew H. Ko, Alan P. Venook, Emily K. Bergsland, Robin Kate Kelley, W. Michael Korn, Elizabeth Dito, Brian Schillinger, Janet H. Scott, Jimmy J. Hwang, Margaret A. Tempero	2010	66
19	Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy Pancreas ·Derrick Wong, Andrew H. Ko, Jimmy J. Hwang, Alan P. Venook, Emily K. Bergsland, Margaret A. Tempero	2008	62
20	Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer British Journal of Cancer ·Andrew H. Ko, Justin H. Hwang, Alan P. Venook, James L. Abbruzzese, Emily K. Bergsland, Margaret A. Tempero	2005	129

About Andrew H. Ko

Andrew H. Ko is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Gastroenterology and Hepatology, having authored 150 papers that have together received 4.9k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (93 papers), Cancer Genomics and Diagnostics (46 papers), Colorectal Cancer Treatments and Studies (24 papers), Cancer Immunotherapy and Biomarkers (20 papers), Renal cell carcinoma treatment (15 papers), Neuroendocrine Tumor Research Advances (15 papers), Gastric Cancer Management and Outcomes (10 papers) and HER2/EGFR in Cancer Research (9 papers). The work is most often cited by research in Oncology (3.8k citations), Cancer Research (1.7k citations), Pulmonary and Respiratory Medicine (963 citations), Immunology (551 citations) and Molecular Biology (1.4k citations). Andrew H. Ko has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Margaret A. Tempero, Alan P. Venook, Eric A. Collisson, Emily K. Bergsland, Grace Kim, Adam B. Olshen, Peter Olson, J. Cooc, William J. Gibb and Heidi S. Feiler. Their work appears in journals such as Journal of Clinical Oncology, Pancreas, Annals of Oncology, The Oncologist and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact